Download PDF

Register to download the report. Already a member?

Sign Up


69986 1521480099HCLSReviewLithuaniaMarch2018.pdf
Energy Boardroom

Pharma Stories & Articles


Diabetes in Lithuania: A Silent Crisis

With over 120,000 people whose lives are affected by the disease in Lithuania; diabetes stands as one of the country’s major health issues today. Furthermore, as Marijus Valatka, general manager for Lithuania, Latvia and Estonia of Novo Nordisk – the …


Cardiology in Poland: Building a Leading Ecosystem

Despite the global R&D excitement around oncology, cardiovascular death still remains the world’s largest killer, and according to OECD data, accounts for roughly a third of all mortalities. This trend is no different in Poland. Nevertheless, the country is taking …


Parallel Trade in Polish Pharma: The Good and the Bad

Poland’s entrance into the EU has been a catalyst for growth that has allowed the country to flourish, shown by the nation’s ranking as the eighth largest economy in Europe according to the World Bank. The introduction into Europe has sprung …


Lithuania’s Biotech Potential

Lithuania’s biotech sector has grown by between 20 and 25 percent over the last five years and accounts for over one percent of the entire country’s GDP. Key industry stakeholders are, however, split on whether Lithuania truly holds the potential …


Indian Biosimilars: Going Global

Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in the next few years and an increasing global focus on …


The Big Chill: Temperature-Sensitive Pharma Logistics in Brazil

When combining the sheer size of Brazil – the fifth largest country in the world – with its tropical climate, its largely perfectible infrastructure, and the soaring importance of temperature sensitive biologicals, one understands the urgent need to develop solutions …


Brazilian Pharma: An Industry on a High

“Brazil undoubtedly holds great development opportunities for the global pharmaceutical and healthcare industries,” boldly states Minister of Health Ricardo Barros, “and we hope to gain the trust of an increasing number of international investors and jointly work on improving the …


Natural Products and Supplements in Serbia: A Growth Spot

In a market environment that, up until recently, has been severely difficult for producers of chemical pharmaceutical products to operate in, three enterprising Serbian companies – Pharmanova, INNventa and Esensa – have found success by stepping up their offering in …


India: Still a Land of Opportunity for MNCs

For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India country president Jawed Zia points out that “India, in terms …


Market Access in Serbia: Steps in the Right Direction

Between 2010 and 2012 just one of the 139 new medicines to receive market authorisations globally was approved for reimbursement in Serbia, compared with 44 in Bulgaria and 27 in Croatia; meaning a severe lack of patient access to much-needed …


Switzerland: The Advent of Drone Delivery

As the spotlight turns towards optimising supply and delivery chains in pharma logistics, Swiss Post has distinguished itself as one of the early movers in trialling autonomous drone logistics for commercial purposes. In March 2017, the company and its partner, …


Québec’s Healthcare Exceptionalism

The government of the French-speaking Canadian province of Québec stands out for undertaking healthcare reforms while appreciating the need to join hands with industry when it comes to the promotion of health innovation. “Quebec has the most aggressive approach of …




Most Read

Download PDF

First Name:

Last Name: